SANES

10.708

+0.19%↑

BBVA

19.545

-0.79%↓

BNP

93.59

-0.52%↓

CABK

11.515

-0.6%↓

INGA

26.21

-1.3%↓

SANES

10.708

+0.19%↑

BBVA

19.545

-0.79%↓

BNP

93.59

-0.52%↓

CABK

11.515

-0.6%↓

INGA

26.21

-1.3%↓

SANES

10.708

+0.19%↑

BBVA

19.545

-0.79%↓

BNP

93.59

-0.52%↓

CABK

11.515

-0.6%↓

INGA

26.21

-1.3%↓

SANES

10.708

+0.19%↑

BBVA

19.545

-0.79%↓

BNP

93.59

-0.52%↓

CABK

11.515

-0.6%↓

INGA

26.21

-1.3%↓

SANES

10.708

+0.19%↑

BBVA

19.545

-0.79%↓

BNP

93.59

-0.52%↓

CABK

11.515

-0.6%↓

INGA

26.21

-1.3%↓

Strona główna・Stock List・Ipsen SA.

Ipsen SA.

Open

SectorFinance

156.1 3.04

Buy Sell

Overview

Share price change

24h

Current

Min

151.4

Max

154.9

Key metrics
By Trading Economics
Income	-225M 110M
Sales	36M 1.9B
P/E Sector Avg	28.534 41.721
Dividend yield	0.89
Profit margin	5.899
Employees	5,535
EBITDA	-171M 466M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	-5.58% downside

Dividends
By Dow Jones
Dividend yield Sector Avg	0.89% 4.65%
Next Earnings	30 lip 2026

Market Stats
By TradingEconomics
Market Cap	1.1B 13B
Previous open	153.06
Previous close	156.1

News Sentiment

By Acuity

42%

58%

120 / 439 Ranking in Finance

Ipsen SA. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 cze 2026, 21:51 UTC

Major Market Movers

Merlin Shares Rally After Defense Department's Design Review Wraps

4 cze 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 cze 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 cze 2026, 23:42 UTC

Acquisitions, Mergers, Takeovers

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 cze 2026, 23:41 UTC

Acquisitions, Mergers, Takeovers

Energy Resources of Australia to Enter Trading Halt

4 cze 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 cze 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 cze 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 cze 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4 cze 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 cze 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4 cze 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4 cze 2026, 20:44 UTC

Acquisitions, Mergers, Takeovers

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 cze 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 cze 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 cze 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 cze 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 cze 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 cze 2026, 18:47 UTC

Acquisitions, Mergers, Takeovers

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 cze 2026, 18:38 UTC

Earnings

Money Quote: Tech Weakness in Context -- WSJ

4 cze 2026, 18:24 UTC

Earnings

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 cze 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 cze 2026, 16:58 UTC

Earnings

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 cze 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 cze 2026, 16:38 UTC

Earnings

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 cze 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4 cze 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4 cze 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 cze 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 cze 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Peer Comparison

Price change

Ipsen SA. Forecast

Price Target

By TipRanks

-5.58% downside

12 Months Forecast

Average 143.8 EUR -5.58%

High 170 EUR

Low 117 EUR

Based on 5 Wall Street analysts offering 12 month price targets forIpsen SA. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Ipsen SA. - Dist in the past 3 months.

Sentiment

By Acuity

120 / 439 Ranking in Finance

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.